ArticleCancer medicine2026
Comparison of Interferon-Based and Interferon-Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus-Sustained Virological Response: A Multicenter Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe examine the impact of interferon (IFN)-based and IFN-free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR).
methodsClinical information was collected on 311 cases of HCC after HCV-SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group. Clinical factors and the tumor microenvironment of HCC after SVR treatment with IFN-based and IFN-free treatments were analyzed.
resultsNo statistically significant differences were observed in the recurrence rate and overall survival (OS) between the two groups. Propensity score-matched analysis similarly showed no statistically significant differences in recurrence and OS. In the IFN-based treatment group, OS time was significantly shorter for the programmed death-ligand 1(PD-L1)-positive HCC than the PD-L1-negative HCC group (p = 0.0183). No significant difference was observed in the recurrence rate between PD-L1-positive and PD-L1-negative HCC groups. In the IFN-based treatment group, the recurrence rate in the cluster of differentiation (CD) 8-positive group was significantly lower than in the CD8-negative group (p = 0.0292). There was no difference in OS time between the CD8-positive and CD8-negative groups. In the IFN-free treatment group, PD-L1 and CD8 were not associated with recurrence rate or OS.
conclusionsNo statistically significant differences were observed in recurrence or OS rate after HCC resection in the IFN-free treatment group compared with the IFN-based treatment group. In the IFN-based treatment group, PD-L1 and CD8 expression on cancer cells might be prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.